Takeda acquires PvP Biologics for $330M following Phase I celiac disease study results
Takeda plans to submit data from the study for later presentation and initiate a Phase IIb trial of the drug, TAK-062, in celiac disease patients. In October, it in-licensed another celiac disease drug, COUR Pharmaceuticals' CNP-101/TAK-101.